In many cancer types where tumors overexpress PD-L1 and PD-L2, anti-PD-1 therapy significantly improves clinical outcomes compared to patients whose tumors have low PD-L1 and PD-L2 expression [98,99,100]. This evidence concerns the gene PDCD1LG2 and cancer.